Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Envigo invests in Science and Technology Advisory Group (STAG)

Posted on: 26 Sep 16

STAG will act as an internal funding body for promising research;  develop new assays and technologies alongside customers; and attract the next generation of scientists


Huntingdon UK, 26 September 2016: Envigo announces the launch of a dedicated Science and Technology Advisory Group (STAG) to drive forward emerging areas of research and to collaborate with customers to develop new technologies.

The STAG group will run across all service offerings of Envigo – including Pharmaceutical Development, Research Models and Services as well as Crop Protection and Chemicals Testing.

The key goal behind the new group is to advance Envigo’s commitment to developing the next generation of research services, technology and science. As such, the group will sponsor internal programmes designed to develop new or improve existing capabilities. Selected external partnerships will also be explored – including collaborations with academia through postdoctoral sponsorship, placement and combined research – along with offering science and technology development services to customers.

Brian Burlinson, Deputy Chair of the STAG, commented: “We are encouraging our scientists to put forward new projects for funding, acting as an internal innovation incubator, but also, we are going out to market and asking our customers if they have research problems they would like us to develop into commercial solutions. However, it’s not just about today’s problems, as we are also partnering with universities, both on developing new science and offering work placements to graduates… our ethos is to instil a culture of new science that permeates all areas of the business.”

Since its inception the group has already reviewed 16 internal applications and spoken with several external partners. One area that is showing a number of promising projects is non animal testing (NAT) for toxicology – in vitro or silico –– as these solutions have the dual benefits of de-risking drug development and meeting the desire for reduced animal use.

“The aim is to generate a balanced portfolio of projects into an annualised programme. Five projects have already been preliminarily approved for development  – with more in the pipeline” added Burlinson.

Another central goal of STAG is to work closely with Envigo’s customers to develop new screening assays – utilising the company's advanced science and technology to meet on-going R&D demands.

One recent example is the development of in vitro assays that enables the testing of 100 or so compounds per month for potential endocrine disrupting effects. A key benefit of these assays is the capability to put fairly large numbers of compounds through the screens with very little material needed for use.

Beyond customer contracts the group is also planning to independently develop new assays and technologies that Envigo can potentially sell to customers in the future.

STAG will also take on a longer term role in the process of attracting talented scientists, particularly high calibre university graduates, including PHDs, who possess specific, specialised skill sets that mirror scientific and technological projects planned or in development at Envigo. This will be achieved through the Science and Technology Advisory Group forming close collaborations with academic institutions and arranging for five or six selected students each year to take up work placements at the company. Envigo has already entered into such an arrangement with Kings College London for students with cardiovascular and pharmacology expertise.  

The STAG will have a core membership of 6-8 representatives for the first 3-years from a range of technical disciplines across the company. However, after this period the STAG committee membership will rotate on 2-year cycles to ensure a regular impetus of new ideas and thinking.



Notes to editors

For media enquiries, please contact:

Alex Heeley or Tristan Jervis        

De Facto Communications

T: +44 (0) 203 735 8166

E: /


Envigo contacts:

Katie Bramwell +44 (0) 1480 892748 / +44 (0) 7894 817428

Ian Cardwell +44 (0) 1480 892379 / +44 (0) 7747 898118


About Envigo

Envigo provides essential products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our company is founded on the principle that research partnerships depend on unmatched expertise, unwavering dedication to customer service and shared goals. With over 3,800 employees across 50+ locations worldwide we are committed to helping customers realize the full potential of their research and products as we work together to build a healthier and safer world.



Editor's Details

Nadine Caillaux
De Facto Communications

Last updated on: 26/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.